Investing Port

P/E	124.34
P/S	167.98
P/BV	10.6
EV/EBITDA	-56.74
EBITDA	-0.23
Цена ао	199.88

Institutions	Объем	Доля, %
Versant Venture Management LLC	3631656	5.1
First Trust Portfolios L.P.	35210	0.05
Financial Trust Asset Management	730	0
Emerge Canada Inc.	23802	0.03
Peroni Portfolio Advisors, Inc	500	0
Abingworth LLP	259599	0.36
SELECTRA MANAGEMENT COMPANY S.A.	32965	0.05
Global X Management Company LLC	49667	0.07
Exchange Traded Concepts, LLC	28874	0.04
American Beacon Advisors Inc	293953	0.41
Nikko Asset Management Co Ltd	1010300	1.42
BlackRock Fund Advisors	729789	1.02
NEA Management Company, LLC	1590002	2.23
Middlefield Capital Corporation	30000	0.04
Shelton Capital Management	64000	0.09
Saint Olive Gestion	65000	0.09
Nikko AM Limited	57018	0.08
Delaware Management Company	471129	0.66
Massachusetts Institute Of Technology	22162	0.03
Invesco Capital Management LLC	99216	0.14
Millington Securities, Inc.	26761	0.04
Middlefield Limited	20000	0.03
Columbia Wanger Asset Management LLC	643047	0.9

ETF	Доля, %	Доходность за год, %
ARK Innovation ETF	5.34	176.62
ARK Genomic Revolution ETF	4.73	221.65
iShares Genomics Immunology and Healthcare ETF	4.75	77.60
Global X Genomics & Biotechnology ETF	5.99	69.62
Loncar Cancer Immunotherapy ETF	4.08	50.95
ERShares Non-US Small Cap ETF	5.31	48.34
Franklin Genomic Advancements ETF	6.01
iShares Morningstar Small-Cap Growth ETF	1.26	51.98
Principal Healthcare Innovators Index ETF	1.72	65.90
Entrepreneur 30 Fund	5.01	56.52
BNY Mellon US Small Cap Core Equity ETF	0.41
Invesco DWA Healthcare Momentum ETF	3.91	87.65
VictoryShares US 500 Enhanced Volatility Weighted ETF	0.3	21.34
VictoryShares US 500 Volatility Weighted Index ETF	0.3	13.40
Timothy Plan US Large Cap Core ETF	0.45	15.94
Virtus LifeSci Biotech Clinical Trials ETF	0.75	43.09
Invesco PureBetaSM MSCI USA Small Cap ETF	0.24	27.86

CRISPR Therapeutics AG, a gene editing company, focuses on developing transformative gene-based medicines for serious human diseases. It develops its products using Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)\u002FCRISPR-associated protein 9 (Cas9), a gene editing technology that allows for precise directed changes to genomic DNA. It has a portfolio of therapeutic programs in a range of disease areas, including hemoglobinopathies, oncology, regenerative medicine, and rare diseases. The company's lead product candidate is CTX001, an ex vivo CRISPR gene-edited therapy for treating patients suffering from transfusion-dependent beta thalassemia or severe sickle cell disease in which a patient's hematopoietic stem cells are engineered to produce high levels of fetal hemoglobin in red blood cells. It is also developing CTX110, a donor-derived gene-edited allogeneic CAR-T therapy targeting cluster of differentiation 19 positive malignancies. In addition, the company is developing allogeneic CAR-T programs comprising CTX120 targeting B-cell maturation antigen for the treatment of multiple myeloma; and CTX130 for the treatment of solid tumors and hematologic malignancies. Further, it engages in developing regenerative medicine programs in diabetes; and in vivo and other genetic disease programs to treat glycogen storage disease Ia, Duchenne muscular dystrophy, and cystic fibrosis. The company has strategic partnerships with Bayer Healthcare LLC, Vertex Pharmaceuticals Incorporated, and ViaCyte, Inc. CRISPR Therapeutics AG is headquartered in Zug, Switzerland.